Navigation Links
New Hope For Patients With Relapsing Multiple Sclerosis

Over two million people worldwide are estimated to suffer from multiple sclerosis (MS), which is the leading cause of neurological disability in young adults, and has a significant impact on the overall quality of life. // Currently marketed therapies afford an average reduction in relapse rates of 30% in two-year studies and require frequent injections ranging from daily to weekly.

Data from the extension of a Phase II study to 12 months conducted by Novartis Pharma confirm the significant effects of FTY720, a novel oral medication, for the treatment of patients with relapsing MS. The data, presented at the ECTRIMS/ACTRIMS meeting in Thessalonica, Greece, showed that patient groups taking FTY720 who had experienced a reduction in their annualized relapse rate of more than 50% during the first 6 months of the study compared to placebo maintained this low relapse rate during the subsequent 6-month extension. More than 80% patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on magnetic resonance imaging (MRI) at month twelve irrespective of their FTY720 treatment dose.

In a press release, chief investigator Professor Ludwig Kappos, MD, Department of Neurology at the University Hospital in Basel, Switzerland said "We are excited by these full-year study results confirming the significant effect of oral FTY720 on reducing both clinical relapses and inflammatory disease activity that we first saw during the 6-month placebo-controlled phase of the study. FTY720 appeared to be well tolerated; there were no complications during the extension as compared to the 6-month placebo-controlled phase.

According to the press release, oral FTY720 has a novel mode of action different from all available therapies. It reversibly sequesters lymphocytes away from blood and susceptible target organs such as the central nervous system (CNS), thereby reducing neuroinflammation in MS. FTY720 has been developed b y Novartis Pharma and licensed from Mitsubishi Pharma Corporation.

Based on the positive results of the Phase II study conducted at 32 centers in 11 countries (Europe and Canada), Novartis is in discussions with regulatory authorities about the FTY720 Phase III program, which is expected to be launched by the end of 2005.

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:

(Date:11/30/2015)... TX (PRWEB) , ... November 30, 2015 , ... ... plastic surgery and dermatology, is proud to announce that its ThermiRFR temperature controlled ... , ThermiRF is an innovative multi-application radiofrequency platform which uses temperature as a ...
(Date:11/30/2015)... ... , ... MOSI recently added two state-of-the-art augmented reality (AR) experiences from INDE ... their collection of interactive exhibits within the Kids In Charge! building. In collaboration with ... get closer than ever to a range of animals as they drink, sleep and ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and ... unit extraction. These techniques and procedures have been in use for many years and ... While Dr. Parsa Mohebi, M.D. has utilized many of these methods over the years, ...
(Date:11/30/2015)... ... November 30, 2015 , ... On Saturday, October 24th, 2015, at the ... annual fundraising event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients ... which is also located in Battle Creek, joined in for this campaign that sought ...
(Date:11/30/2015)... ... , ... The presidential race normally deals with political issues of national importance ... news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? It is ... wants to admit when it comes to how people are viewed by others. , ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BANNOCKBURN, Ill. , Nov. 30, 2015 ... ), a global biopharmaceutical leader dedicated to ... diseases and underserved medical conditions, today announced ... [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating ... hemophilia A based on full-length ADVATE [Antihemophilic ...
(Date:11/30/2015)... HONG KONG, Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September ... Service Income , 421,979 , 384,242 ... , 34,719 , (18.3) Medical ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , ...
(Date:11/30/2015)... November 30, 2015 --> ... "Dental Lasers Market by Product (Soft Tissue, All Tissue, Dental ... (Hospitals, Clinics), and Geography - Global Forecast to 2020", published ... 2020, at a CAGR of 5.2% during the forecast period ... data Tables and 62 Figures spread through 167 P ...
Breaking Medicine Technology: